 | Up a level |
Francis, PA; Pagani, O; Fleming, GF; Walley, BA; Colleoni, M; Láng, I; Gómez, HL; Tondini, C; Ciruelos, E; Burstein, HJ; Bonnefoi, HR; Bellet, M; Martino, S; Geyer, Jr. CE; Goetz, MP; Stearns, V; Pinotti, G; Puglisi, F; Spazzapan, S; Climent, MA; ... (2018). Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. New England journal of medicine NEJM, 379(2), pp. 122-137. Massachusetts Medical Society MMS 10.1056/NEJMoa1803164
Rabaglio, M; Sun, Z; Price, K N; Castiglione-Gertsch, M; Hawle, H; Thürlimann, B; Mouridsen, H; Campone, M; Forbes, J F; Paridaens, R J; Colleoni, M; Pienkowski, T; Nogaret, J-M; Láng, I; Smith, I; Gelber, R D; Goldhirsch, A; Coates, A S (2009). Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Annals of oncology, 20(9), pp. 1489-98. Oxford: Oxford University Press 10.1093/annonc/mdp033
Mauriac, L; Keshaviah, A; Debled, M; Mouridsen, H; Forbes, JF; Thürlimann, B; Paridaens, R; Monnier, A; Láng, I; Wardley, A; Nogaret, JM; Gelber, RD; Castiglione-Gertsch, M; Price, KN; Coates, AS; Smith, I; Viale, G; Rabaglio, M; Zabaznyi, N; Goldhirsch, A; ... (2007). Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Annals of oncology, 18(5), pp. 859-67. Oxford: Oxford University Press 10.1093/annonc/mdm001
